Effects of anabolic androgenic steroids on chylomicron metabolism

Autor(es)

Morikawa, Aleksandra T. ^[1] ; Maranhao, Raul C. ^{[2, 1]} ; Alves, Maria-Janieire N. N. ^[1] ; Negrao, Carlos E. ^[1] ; da Silva, Jeferson L. ^[1] ; Vinagre, Carmen G. C. ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Med Sch Hosp, Heart Inst InCor, Sao Paulo - Brazil

^[2] Univ Sao Paulo, Fac Pharmaceut Sci, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Steroids; v. 77, n. 13, p. 1321-1326, NOV 2012.
• Citações Web of Science: 3

Resumo

Objective: To evaluate the effects of anabolic androgenic steroids (AAS) on chylomicron metabolism. Methods: An artificial lipid emulsion labeled with radioactive cholesteryl ester (CE) and triglycerides (TG) mimicking chylomicrons was intravenously injected into individuals who regularly weight trained and made regular use of AAS (WT + AAS group), normolipidemic sedentary individuals (SDT group) and individuals who also regularly weight trained but did not use AAS (WT group). Fractional clearance rates (FCR) were determined by compartmental analysis for emulsion plasma decay curves. Results: FCR-CE for the WT + AAS group was reduced (0.0073 +/- 0.0079 min(-1), 0.0155 +/- 0.0100 min(-1), 0.0149 +/- 0.0160 min(-1), respectively; p<0.05), FCR-TG was similar for both the WT and SDT groups. HDL-C plasma concentrations were lower in the WT + AAS group when compared to the WT and SDT groups (22 +/- 13; 41 +/- 38 +/- 13 mg/dL, respectively; p<0.001). Hepatic triglyceride lipase activity was greater in the WT + AAS group when compared to the WT and SDT groups (7243 +/- 1822; 3898 +/- 1232; 2058 +/- 749, respectively; p<0.001). However, no difference was observed for lipoprotein lipase activity. Conclusions: Data strongly suggest that AAS may reduce the removal from the plasma of chylomicron remnants, which are known atherogenic factors. (C) 2012 Elsevier Inc. All rights reserved. (AU)

• Processo FAPESP: 06/58917-3 - Nanopartículas lipídicas: aplicações no estudo da fisiopatologia, diagnóstico e terapêutica das doenças degenerativas
• Beneficiário: Raul Cavalcante Maranhao
• Modalidade de apoio: Auxílio à Pesquisa - Temático